Heart News and Research

RSS

Case study of multi-system inflammatory syndrome in children in a fully vaccinated teenager

A new preprint describes the importance of recognizing this complication, reporting a case of MIS-C without a prior history of this infection.

4 Apr 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater reductions in three key measures of plaque vulnerability that signal risk for future cardiac events, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

3 Apr 2022

Customized digital alert improves guideline-directed medical therapy for heart failure

Physicians prescribed significantly more guideline-directed medications for heart failure if they received a customized digital alert via an electronic health record (EHR) system when inputting medical orders shortly after seeing a patient, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patients with heart failure with reduced ejection fraction (HFrEF) did not experience any improvement in their ability to exercise vigorously after taking the experimental heart failure drug omecamtiv mecarbil, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Leakage after left atrial appendage occlusion associated with higher risk of adverse events

Patients who had leakage to the left atrial appendage due to incomplete device sealing after left atrial appendage occlusion (LAAO) experienced more clotting and bleeding events within a year following their procedure compared with patients who had no leaking, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Smartwatch application can be used for atrial fibrillation screening

Atrial fibrillation (AFib) was confirmed in nearly 94% of people who were initially identified to have signs of the heart rhythm disorder by a smartwatch application and who followed up with a clinician, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Global study demonstrates some benefits of flu vaccine in people with heart failure

People with heart failure who received an annual flu shot had lower rates of pneumonia and hospitalization on a year-round basis and a reduction in major cardiovascular events during peak flu season, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

First practical guide on the use of digital devices for heart rhythm and rate monitoring published

Who should monitor their heart rate and rhythm and which device should they use? Find out in an international consensus document published today in EP Europace, a journal of the European Society of Cardiology (ESC) and presented at EHRA 2022, a scientific congress of the ESC.

3 Apr 2022

Recommendations to prevent, manage interference in patients with implanted cardiac devices

Recommendations on the prevention and management of interference caused by medical procedures in patients with implanted electronic cardiac devices is published today in EP Europace, a journal of the European Society of Cardiology and presented at EHRA 2022, a scientific congress of the ESC.

3 Apr 2022

Hypertension treatment during pregnancy benefits pregnant women and their babies

Adults treated with medication for high blood pressure present before or during the first 20 weeks of pregnancy, defined as chronic hypertension in pregnancy, had fewer adverse pregnancy outcomes compared to adults who did not receive antihypertensive treatment, according to a study supported by the National Institutes of Health.

2 Apr 2022

Cedars-Sinai’s Los Angeles Barbershop Blood Pressure Study delivers new insights

The Los Angeles Barbershop Blood Pressure Study is delivering cutting-edge insights more than four years after the study results were published in The New England Journal of Medicine.

2 Apr 2022

New evidence on how salt reduction can benefit heart failure patients

For the past century people with weak hearts have been told to lower their salt intake, but until now there has been little scientific evidence behind the recommendation.

2 Apr 2022

High caffeine consumption induces ventricular tachyarrhythmias in rats

The Food and Drug Administration recommends healthy adults not exceed 400 milligrams (mg) of caffeine- approximately four cups of brewed coffee- a day.

2 Apr 2022

Virtual population used to replicate a clinical trial that examines kidney damage in Black Americans

Researchers have successfully used a virtual population to replicate a clinical trial that examined kidney damage in Black Americans, according to a new study at the University of Mississippi Medical Center in Jackson. John S. Clemmer, PhD, a physiologist and lead author of the study, said his team model used a calcium channel blocker to predict kidney damage.

2 Apr 2022

Heart News and Research

Case study of multi-system inflammatory syndrome in children in a fully vaccinated teenager

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

Customized digital alert improves guideline-directed medical therapy for heart failure

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Leakage after left atrial appendage occlusion associated with higher risk of adverse events

Smartwatch application can be used for atrial fibrillation screening

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Global study demonstrates some benefits of flu vaccine in people with heart failure

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

First practical guide on the use of digital devices for heart rhythm and rate monitoring published

Recommendations to prevent, manage interference in patients with implanted cardiac devices

Hypertension treatment during pregnancy benefits pregnant women and their babies

Cedars-Sinai’s Los Angeles Barbershop Blood Pressure Study delivers new insights

New evidence on how salt reduction can benefit heart failure patients

High caffeine consumption induces ventricular tachyarrhythmias in rats

Virtual population used to replicate a clinical trial that examines kidney damage in Black Americans

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News